Genmab A/S - American Depositary Shares (GMAB)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Aug 24, 2026Investment Snapshot
- Trading 81% below Graham Number ($175.22) — significant margin of safety
- Piotroski F-Score 4/9 — moderate financial health
- ROE of 16.5% — good return on equity
- Revenue growing at 19% annually
Genmab A/S - American Depositary Shares (GMAB) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $2.1 billion . Key value metrics: P/E ratio 2.2, P/B ratio 0.37, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Genmab A/S - American Depositary Shares — Fundamental Analysis Summary
Genmab A/S - American Depositary Shares (GMAB) is trading 81% below its Graham Number of $175.22 — a significant margin of safety by Benjamin Graham's standard. The stock carries a low trailing P/E ratio of 2.2x.
On financial health, GMAB shows a moderate Piotroski F-Score of 4/9, and solid return on equity of 16.5% (sector average: -20.1%), and manageable leverage with a debt-to-equity ratio of 0.90.
StockPik's composite Value Score for GMAB is 100/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
GMAB reports a high gross margin of 93.6% (sector average: 37.4%) and a strong operating margin of 28.6%.
GMAB shows revenue growing at 19% year-over-year, with earnings declining at 15%.